Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, September 3, 2013 NEW YORK, September 3, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting CareFusion Corporation (NYSE: CFN), St. Jude Medical, Inc. (NYSE: STJ), Community Health Systems Inc. (NYSE: CYH), Neurocrine Biosciences, Inc. (NASDAQ: NBIX), and Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. CareFusion Corporation Research Report On August 27, 2013, CareFusion Corporation (CareFusion) announced that the Company has simplified the ordering process for its line of surgical products through an interactive e-catalog portal. According to CareFusion, the new time-saving ordering system includes more than 12,000 different products that are easily searched and sorted based on the product name or the type of specialty in which they are used. CareFusion informed that the new system includes pre-built and recommended trays for more than 25 common procedures from nine different specialty areas including Cardiovascular, Ear Nose and Throat, General and Micro Surgery, Laparoscopic Surgery, Neurology and Spine, Obstetrics and Gynecology, Ophthalmic, Oral Surgery, and Orthopedic. The Full Research Report on CareFusion Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4933_CFN] St. Jude Medical, Inc. Research Report On August 29, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that it has bagged the CE Mark approval for its EnligHTN Renal Denervation System which is used to treat patients with drug-resistant uncontrolled hypertension. According to the Company, the new system has an advanced generator that delivers simultaneous ablations through a multi-electrode catheter, which reduces total ablation time from c.24 minutes required by the first generation system to four minutes by the new system. Frank J. Callaghan, President of the St. Jude Medical Cardiovascular and Ablation Technologies Division, said, "The next generation EnligHTN system offers physicians our proven multi-electrode catheter with a new intuitive, faster generator that quickly and effectively delivers consistent ablations with a significant reduction in procedure time. These advancements deliver on our strategy to bring new innovations to a developing market to provide options for patients who currently do not have an adequate treatment for their uncontrolled drug-resistant hypertension." The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b338_STJ] Community Health Systems Inc. Research Report On August 22, 2013, Community Health Systems Inc. (CHS) and Cleveland Clinic announced that they have been selected for exclusive negotiations in relation to the purchase of certain assets of Akron General Health System. According to the Company, the assets include Akron General Medical Center - a 532-bed acute care hospital in Akron, Ohio; 70-bed Edwin Shaw Rehabilitation Hospital in Cuyahoga Falls, Ohio; Lodi Community Hospital - a 25-bed critical access hospital c.30 miles west of Akron, and other related healthcare facilities and services. Community Health Systems stated that the parties will complete the due diligence process and work toward finalizing the terms of a definitive agreement. Wayne T. Smith, Chairman, President and CEO of CHS said, "The strategic alliance formed between Cleveland Clinic and Community Health Systems earlier this year is gaining momentum as we work together to advance high-quality, cost-effective healthcare services within our own organizations," The Full Research Report on Community Health Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7587_CYH] Neurocrine Biosciences, Inc. Research Report On August 29, 2013, Neurocrine Biosciences Inc. (Neurocrine Biosciences) announced that in accordance to the Company's collaboration with AbbVie for elagolix in 2010, the latter has initiated the second Phase III pivotal trial to evaluate elagolix for the treatment of endometriosis. Neurocrine Biosciences informed that the second Phase III trial is a 24-week, multinational, randomized double-blind placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 788 women, age 18-49, with moderate-to-severe endometriosis-associated pain. The Company expects to provide top-line data from the second Phase III trial in Q3 2014 and complete in 2015. The Full Research Report on Neurocrine Biosciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8228_NBIX] Alnylam Pharmaceuticals Inc. Research Report On August 28, 2013, Alnylam Pharmaceuticals Inc. (Alnylam) announced the publication of complete study results from Phase I trials with ALN-TTR0a and ALN-TTR02 in a article titled "Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis" in the New England Journal of Medicine. Alnylam informed that the article shows that RNAi therapeutics targeting transthyretin (TTR) achieved rapid, dose-dependent, durable, and specific knockdown of the TTR, the disease causing protein in the TTR mediated amyloidosis (ATTR). Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam, said, "The Phase I studies of ALN-TTR01 and ALN-TTR02 demonstrate key human proof of concept for RNAi therapeutics targeting TTR but also for liver-expressed target genes in general, and we are thrilled to be publishing these landmark data in the New England Journal of Medicine. Notably, this is the first time that clinical results with an RNAi therapeutic have been published in the Journal, and we are proud to be associated with this milestone as we lead the clinical translation of RNAi therapeutics as a whole new class of innovative medicines."The Full Research Report on Alnylam Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5b29_ALNY] EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. www.AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community
Press spacebar to pause and continue. Press esc to stop.